Reneo Pharmaceuticals (RPHM) Receives a Buy from Robert W. Baird

In a report issued on July 26, Brian Skorney from Robert W. Baird maintained a Buy rating on Reneo Pharmaceuticals (RPHMResearch Report), with a price target of $28.00. The company’s shares closed last Thursday at $3.60.

According to, Skorney ‘s ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -7.1% and a 42.6% success rate. Skorney covers the Healthcare sector, focusing on stocks such as Eiger Biopharmaceuticals, Vertex Pharmaceuticals, and Enanta Pharmaceuticals.

Currently, the analyst consensus on Reneo Pharmaceuticals is a Strong Buy with an average price target of $28.00, which is a 665.0% upside from current levels. In a report issued on July 26, Piper Sandler also maintained a Buy rating on the stock with a $25.00 price target.

See today’s best-performing stocks on TipRanks >>

The company has a one-year high of $11.40 and a one-year low of $1.92. Currently, Reneo Pharmaceuticals has an average volume of 102.6K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Reneo Pharmaceuticals Inc is a clinical stage pharmaceutical company. It is focused on the development of therapies for patients with rare genetic mitochondrial diseases, which are often associated with the inability of mitochondria to produce adenosine triphosphate (ATP). The company is developing REN001 to modulate genes critical to metabolism and generation of ATP, which is the primary source of energy for cellular processes.

Read More on RPHM:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More